OBJECTIVE: This functional magnetic resonance imaging (fMRI) study investigated the effects of pharmacotherapy on brain function underlying affect dysregulation and cognitive function in pediatric bipolar disorder (PBD). METHOD: Healthy controls (HC) (n=14; mean age =14.1 ± 2.4 years) and unmedicated PBD patients with manic or hypomanic episodes (n=17; mean age =14.3 ± 1.1 years) were matched on intelligence quotient (IQ) and demographic factors. The fMRI studies were performed at baseline and after 14 weeks, during which PBD patients were treated initially with second-generation antipsychotics (SGAs) followed by lamotrigine monotherapy. The pediatric affective color-matching task was used where subjects matched the color of a positive, negative, or neutral word with one of the two colored circles below in each of the trials. There were five blocks of each emotional word type, with 10 trials per block. RESULTS: Behavioral data showed that the PBD group was modestly slower and less accurate than the HC, regardless of condition or treatment status. The blood oxygen level-dependent (BOLD) signal activity was reduced with treatment in the PBD group relative to the HC group during the negative versus neutral condition in bilateral dorsolateral prefrontal cortex (DLPFC), right posterior cingulate gyrus, parahippocampal gyrus, and inferior parietal lobule, but increased in left ventromedial prefrontal cortex (VMPFC). Similarly, during the positive versus neutral condition, the PBD group, relative to HC, showed reduced activity in right DLPFC, precuneus, and inferior parietal lobule and increased activity in the right VMPFC. However, within the PBD group, there was treatment related decrease in VMPFC and DLPFC. Improvement on Young Mania Rating Scale (YMRS) score significantly correlated with the decreased activity in VMPFC within the patient group. CONCLUSIONS: Pharmacotherapy in PBD patients led to differential effort with persistently increased activity in the affective regions and decreased activity in the cognitive regions relative to HC, demonstrating altered mechanisms of affective and cognitive systems of brain function, regardless of symptom response.
OBJECTIVE: This functional magnetic resonance imaging (fMRI) study investigated the effects of pharmacotherapy on brain function underlying affect dysregulation and cognitive function in pediatric bipolar disorder (PBD). METHOD: Healthy controls (HC) (n=14; mean age =14.1 ± 2.4 years) and unmedicated PBD patients with manic or hypomanic episodes (n=17; mean age =14.3 ± 1.1 years) were matched on intelligence quotient (IQ) and demographic factors. The fMRI studies were performed at baseline and after 14 weeks, during which PBD patients were treated initially with second-generation antipsychotics (SGAs) followed by lamotrigine monotherapy. The pediatric affective color-matching task was used where subjects matched the color of a positive, negative, or neutral word with one of the two colored circles below in each of the trials. There were five blocks of each emotional word type, with 10 trials per block. RESULTS: Behavioral data showed that the PBD group was modestly slower and less accurate than the HC, regardless of condition or treatment status. The blood oxygen level-dependent (BOLD) signal activity was reduced with treatment in the PBD group relative to the HC group during the negative versus neutral condition in bilateral dorsolateral prefrontal cortex (DLPFC), right posterior cingulate gyrus, parahippocampal gyrus, and inferior parietal lobule, but increased in left ventromedial prefrontal cortex (VMPFC). Similarly, during the positive versus neutral condition, the PBD group, relative to HC, showed reduced activity in right DLPFC, precuneus, and inferior parietal lobule and increased activity in the right VMPFC. However, within the PBD group, there was treatment related decrease in VMPFC and DLPFC. Improvement on Young Mania Rating Scale (YMRS) score significantly correlated with the decreased activity in VMPFC within the patient group. CONCLUSIONS: Pharmacotherapy in PBD patients led to differential effort with persistently increased activity in the affective regions and decreased activity in the cognitive regions relative to HC, demonstrating altered mechanisms of affective and cognitive systems of brain function, regardless of symptom response.
Authors: Felix Bermpohl; Alvaro Pascual-Leone; Amir Amedi; Lotfi B Merabet; Felipe Fregni; Nadine Gaab; David Alsop; Gottfried Schlaug; Georg Northoff Journal: Hum Brain Mapp Date: 2006-08 Impact factor: 5.038
Authors: Brendan A Rich; Deborah T Vinton; Roxann Roberson-Nay; Rebecca E Hommer; Lisa H Berghorst; Erin B McClure; Stephen J Fromm; Daniel S Pine; Ellen Leibenluft Journal: Proc Natl Acad Sci U S A Date: 2006-05-30 Impact factor: 11.205
Authors: Brendan A Rich; Mariana Schmajuk; Koraly E Perez-Edgar; Daniel S Pine; Nathan A Fox; Ellen Leibenluft Journal: Biol Psychiatry Date: 2005-06-13 Impact factor: 13.382
Authors: Mani N Pavuluri; James A Ellis; Ezra Wegbreit; Alessandra M Passarotti; Michael C Stevens Journal: Behav Brain Res Date: 2011-10-08 Impact factor: 3.332
Authors: Mani N Pavuluri; Alessandra M Passarotti; Jacklynn M Fitzgerald; Ezra Wegbreit; John A Sweeney Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-12-23 Impact factor: 8.829
Authors: Ezra Wegbreit; James A Ellis; Aneesh Nandam; Jacklynn M Fitzgerald; Alessandra M Passarotti; Mani N Pavuluri; Michael C Stevens Journal: Brain Connect Date: 2011-12-07
Authors: Michele A Bertocci; Genna Bebko; Amanda Dwojak; Satish Iyengar; Cecile D Ladouceur; Jay C Fournier; Amelia Versace; Susan B Perlman; Jorge R C Almeida; Michael J Travis; Mary Kay Gill; Lisa Bonar; Claudiu Schirda; Vaibhav A Diwadkar; Jeffrey L Sunshine; Scott K Holland; Robert A Kowatch; Boris Birmaher; David Axelson; Sarah M Horwitz; Thomas Frazier; L Eugene Arnold; Mary A Fristad; Eric A Youngstrom; Robert L Findling; Mary L Phillips Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-05